trending Market Intelligence /marketintelligence/en/news-insights/trending/2eedgi9bwnexgeajxf1nzq2 content esgSubNav
In This List

Halozyme appoints former Bristol-Myers exec as chief commercial officer

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Halozyme appoints former Bristol-Myers exec as chief commercial officer

Halozyme Therapeutics Inc. appointed Benjamin Hickey as chief commercial officer, effective Sept. 10.

The San Diego-based company said Hickey will build and execute the commercial strategy for its oncology portfolio, beginning with the investigational drug pegvorhyaluronidase alfa, or PEGPH20, if approved.

Hickey previously served as general manager for U.K. and Ireland at Bristol-Myers Squibb Co. During his 17-year career at Bristol-Myers, Hickey also served as vice president of marketing for immuno-oncology, where he led the commercialization of blockbuster cancer drug Yervoy and oversaw the launch preparedness of Opdivo, another blockbuster cancer drug.